Skip to content

Insulin Resistance in HCV Infection

Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01858012
Enrollment
250
Registered
2013-05-20
Start date
2008-01-01
Completion date
2026-12-31
Last updated
2025-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance

Keywords

insulin resistance

Brief summary

The study hypothesis is that the means by which HCV induces glucose intolerance is through impairment of B-cell function and compensatory hyperinsulinemia in predisposed Latinos with insulin resistance and that HCV eradication improves these abnormalities. It is also hypothesized that moderate alcohol consumption impact insulin sensitivity and secretion with Latinos with or without HCV infection.

Detailed description

The study hypothesis is that the means by which HCV induces glucose intolerance is through impairment of B-cell function and compensatory hyperinsulinemia in predisposed Latinos with insulin resistance and that HCV eradication improves these abnormalities. This study addresses changes in the metabolic parameters over time. In addition, it is hypothesized that moderate alcohol consumption impacts insulin resistance and secretion and 30 patients with or without HCV who drink alcohol moderately will have discontinuation of alcohol use for 6 weeks and have metabolic testing before and after alcohol discontinuation.

Interventions

BEHAVIORALModerate alcohol cessation

patients will have moderate alcohol use discontinued for 6 weeks and have before and after alcohol cessation clinical and metabolic assessment and also patients with hepatitis C who have undergo therapy for hepatitis C may have repeat clinical and metabolic assessement

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

for HCV participants: * Male or female patients between 18 and 60 years of age * Body mass index (BMI) \> 20 Kg/m2 * Serologic evidence of hepatitis C infection by anti-HCV antibody * Detectable plasma HCV-RNA * Compensated liver disease with the following minimum biochemical parameters: prothrombin time \< 2 seconds prolonged compared to control and bilirubin \< 3 mg/dL * Willingness to provide informed consent Inclusion criteria for healthy Latino volunteers (without HCV infection): -Same inclusion criteria as above except no evidence of HCV infection (anti-HCV antibody negative) Inclusion criteria for participation in 6-week alcohol abstinence follow-up testing: -Latinos who are moderate1 alcohol drinkers (1NIAAA definition: female: no more than 3 drinks on any day & no more than 7 drinks per week; male: no more than 4 drinks on any day and no more than 14 drinks per week). Steady-State Plasma Glucose \< 180 mg/dL

Exclusion criteria

* Hepatitis B or HIV infection * Subjects with liver disease other than that caused by HCV * Known history of diabetes, or fasting plasma glucose concentration \>126 mg/dl * Known history of cirrhosis of the liver, as well as individuals with decompensated liver disease such as those with ascites, variceal bleeding, and encephalopathy * Known history of pancreatitis * Prior or current treatment for HCV * Heavy alcohol use (\>80 g/d) * Subjects of lipid lowering agents, steroid/ anabolic therapy * Significant medical illness that would interfere with the completion of the study

Design outcomes

Primary

MeasureTime frameDescription
insulin resistancebaseline, 6 weeks and 18 monthssteady state plasma glucose level (mg/dL)

Secondary

MeasureTime frameDescription
Insulin secretionbaseline, 6 weeks and 18 monthsinsulin secretion rate area under the curve (pmol/min)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026